Analyst firms · Morgan Stanley · IART
Morgan Stanley IART price target and rating history
Integra LifeSciences Holdings Corporation (IART) · Health Care
Morgan Stanley rates Integra LifeSciences Holdings Corporation (IART) Underweight with a $20 price target, as of its latest action on Dec 2, 2024. It has published 3 rating actions on IART since July 2022, including 0 upgrades and 1 downgrade. Across 4 firms with a IART price target in the last 12 months, the median target is $19.
- Current rating
- Underweight
- Price target
- $20
- Median target, all firms
- $19
- Actions on IART
- 3
Morgan Stanley price target on IART
Every Morgan Stanley rating on IART
- Dec 2, 2024
- Aug 24, 2023
- Jul 25, 2022
How other firms rate IART
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Neutral | $19 | Jul 28, 2026 |
| BMO Capital Markets | Market Perform | $19 | Jul 9, 2026 |
| Argus Research | Buy | $25 | Jun 18, 2026 |
| Citigroup | Neutral | $16 | May 28, 2026 |
Questions about Morgan Stanley and IART
- What is Morgan Stanley's price target for IART?
- Morgan Stanley's latest stated price target for Integra LifeSciences Holdings Corporation (IART) is $20, from its action on Dec 2, 2024.
- What is Morgan Stanley's rating on IART?
- Morgan Stanley rates IART Underweight, a bearish rating, as of Dec 2, 2024.
- When did Morgan Stanley last change its view on IART?
- On Dec 2, 2024, Morgan Stanley starts coverage at Underweight, price target $25 to $20.
- How does Morgan Stanley's IART target compare with other analysts?
- Across 4 firms with a IART price target in the last 12 months, the median target is $19.
More IART rating histories
All Morgan Stanley ratingsIART news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.